prostatic neoplasms

Summary

Summary: Tumors or cancer of the prostate.

Top Publications

  1. ncbi Prospective identification of tumorigenic prostate cancer stem cells
    Anne T Collins
    Yorkshire Cancer Research Unit, Department of Biology, University of York, York, United Kingdom
    Cancer Res 65:10946-51. 2005
  2. pmc Integrative genomic profiling of human prostate cancer
    Barry S Taylor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Cell 18:11-22. 2010
  3. ncbi Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
  4. ncbi Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
    Science 310:644-8. 2005
  5. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
  6. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
  7. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
  8. ncbi Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome
    Vincent C Lombardi
    Whittemore Peterson Institute, Reno, NV 89557, USA
    Science 326:585-9. 2009
  9. pmc The genomic complexity of primary human prostate cancer
    Michael F Berger
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 470:214-20. 2011
  10. ncbi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009

Detail Information

Publications279 found, 100 shown here

  1. ncbi Prospective identification of tumorigenic prostate cancer stem cells
    Anne T Collins
    Yorkshire Cancer Research Unit, Department of Biology, University of York, York, United Kingdom
    Cancer Res 65:10946-51. 2005
    ..The identification of a prostate cancer stem cell provides a powerful tool to investigate the tumorigenic process and to develop therapies targeted to the stem cell...
  2. pmc Integrative genomic profiling of human prostate cancer
    Barry S Taylor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Cell 18:11-22. 2010
    ..The genomic and clinical outcome data from these patients are now made available as a public resource...
  3. ncbi Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
    ..Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer...
  4. ncbi Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
    Science 310:644-8. 2005
    ..These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer...
  5. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
    ..We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy...
  6. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
    ..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
  7. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    ..We compared such treatment with docetaxel plus prednisone in men with this disease...
  8. ncbi Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome
    Vincent C Lombardi
    Whittemore Peterson Institute, Reno, NV 89557, USA
    Science 326:585-9. 2009
    ..These findings raise the possibility that XMRV may be a contributing factor in the pathogenesis of CFS...
  9. pmc The genomic complexity of primary human prostate cancer
    Michael F Berger
    The Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
    Nature 470:214-20. 2011
    ..Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms...
  10. ncbi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
    ..The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer...
  11. ncbi PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    J Li
    Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
    Science 275:1943-7. 1997
    ..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
  12. pmc Radical prostatectomy versus observation for localized prostate cancer
    Timothy J Wilt
    Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs VA Health Care System, and Section of General Medicine, University of Minnesota School of Medicine, Minneapolis, USA
    N Engl J Med 367:203-13. 2012
    ..The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known...
  13. ncbi The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  14. pmc Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
    Arun Sreekumar
    The Michigan Center for Translational Pathology, Ann Arbor, USA
    Nature 457:910-4. 2009
    ..Here, by profiling the metabolomic alterations of prostate cancer progression, we reveal sarcosine as a potentially important metabolic intermediary of cancer cell invasion and aggressivity...
  15. pmc Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
    Zhenbang Chen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 436:725-30. 2005
    ..Our results demonstrate the relevance of cellular senescence in restricting tumorigenesis in vivo and support a model for cooperative tumour suppression in which p53 is an essential failsafe protein of Pten-deficient tumours...
  16. ncbi Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Daniel P Petrylak
    Columbia University, Herbert Irving Comprehensive Cancer Center, New York, USA
    N Engl J Med 351:1513-20. 2004
    ..We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer...
  17. pmc Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant
    Anatoly Urisman
    Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America
    PLoS Pathog 2:e25. 2006
    ..These findings also raise questions about the possible relationship between exogenous infection and cancer development in genetically susceptible individuals...
  18. ncbi International variation in prostate cancer incidence and mortality rates
    Melissa M Center
    Intramural Research, American Cancer Society, Atlanta, GA 30303 1002, USA
    Eur Urol 61:1079-92. 2012
    ..Wide variation exists internationally for prostate cancer (PCa) rates due to differences in detection practices, treatment, and lifestyle and genetic factors...
  19. ncbi Prostate-cancer mortality at 11 years of follow-up
    Fritz H Schroder
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 366:981-90. 2012
    ..We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up...
  20. pmc The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
    Can Liu
    Department of Molecular Carcinogenesis, The University of Texas M D Anderson Cancer Center, Science Park, Smithville, Texas, USA
    Nat Med 17:211-5. 2011
    ..Our study shows that miR-34a is a key negative regulator of CD44(+) prostate cancer cells and establishes a strong rationale for developing miR-34a as a novel therapeutic agent against prostate CSCs...
  21. ncbi Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    Johann Sebastian de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Lancet 376:1147-54. 2010
    ..We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment...
  22. pmc Changes in circulating microRNA levels associated with prostate cancer
    R J Bryant
    Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
    Br J Cancer 106:768-74. 2012
    ..The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer...
  23. pmc XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors
    Robert Schlaberg
    Department of Pathology and Cell Biology, Columbia University Medical Center, 622 West 168th Street, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 106:16351-6. 2009
    ..Our observations provide evidence for an association of XMRV with malignant cells and with more aggressive tumors...
  24. ncbi The development of androgen-independent prostate cancer
    B J Feldman
    Department of Medicine, Stanford University School of Medicine, California 94305 5103, USA
    Nat Rev Cancer 1:34-45. 2001
    ....
  25. ncbi MicroRNA expression profiling in prostate cancer
    Kati P Porkka
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Cancer Res 67:6130-5. 2007
    ....
  26. ncbi Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
    Annika Schaefer
    Department of Biology, Free University, Berlin, Germany
    Int J Cancer 126:1166-76. 2010
    ..Thus, differential miRNAs in prostate cancer are useful diagnostic and prognostic indicators. This study provides a solid basis for further functional analyses of miRNAs in prostate cancer...
  27. ncbi EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
    Axel Heidenreich
    Department of Urology, RWTH University Aachen, Aachen, Germany
    Eur Urol 59:61-71. 2011
    ..Our aim was to present a summary of the 2010 version of the European Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically localised cancer of the prostate (PCa)...
  28. pmc Disease-associated XMRV sequences are consistent with laboratory contamination
    Stephane Hue
    MRC Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland St, London W1T 4JF, UK
    Retrovirology 7:111. 2010
    ..Controversy has arisen from the failure of some studies to detect XMRV in PC or CFS patients and from inconsistent detection of XMRV in healthy controls...
  29. ncbi Widespread deregulation of microRNA expression in human prostate cancer
    M Ozen
    Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    Oncogene 27:1788-93. 2008
    ..Our findings indicate that changes in miRNA expression may have an important role in the biology of human prostate cancer...
  30. pmc Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
    Yingming Li
    Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Res 73:483-9. 2013
    ....
  31. pmc An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression
    Jindan Yu
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 17:443-54. 2010
    ..These findings provide a working model in which TMPRSS2-ERG plays a critical role in cancer progression by disrupting lineage-specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program...
  32. pmc Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer
    Stefan Ambs
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4258, USA
    Cancer Res 68:6162-70. 2008
    ..In summary, microRNA expression becomes altered with the development and progression of prostate cancer. Some of these microRNAs regulate the expression of cancer-related genes in prostate cancer cells...
  33. ncbi The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
    Jonathan I Epstein
    Department of Pathology, Urology and Oncology, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Am J Surg Pathol 29:1228-42. 2005
  34. pmc Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
    Brett S Carver
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:575-86. 2011
    ....
  35. ncbi MicroRNA in prostate, bladder, and kidney cancer: a systematic review
    James W F Catto
    Institute for Cancer Studies and Academic Urology Unit, University of Sheffield, Sheffield, UK
    Eur Urol 59:671-81. 2011
    ..Their altered expression and function have been observed in most urologic cancers. MiRNAs represent potential disease biomarkers and novel therapeutic targets...
  36. ncbi Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
    JAMA 280:969-74. 1998
    ..Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known...
  37. ncbi XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH
    Rebecca S Arnold
    Department of Urology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Urology 75:755-61. 2010
    ....
  38. pmc Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
    Qianben Wang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cell 138:245-56. 2009
    ..Thus, the role of AR in androgen-independent cancer cells is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth...
  39. pmc Recombinant origin of the retrovirus XMRV
    Tobias Paprotka
    Viral Mutation Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Science 333:97-101. 2011
    ....
  40. ncbi Quality of life and satisfaction with outcome among prostate-cancer survivors
    Martin G Sanda
    Departments of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard University, Boston, MA 02215, USA
    N Engl J Med 358:1250-61. 2008
    ....
  41. ncbi Metastasis to bone: causes, consequences and therapeutic opportunities
    Gregory R Mundy
    Department of Molecular Medicine, University of Texas Health Science Center, 7703 Floyd Curl Drive, MS 7877, San Antonio, Texas 78229 3900, USA
    Nat Rev Cancer 2:584-93. 2002
    ....
  42. ncbi Molecular determinants of resistance to antiandrogen therapy
    Charlie D Chen
    Department of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Nat Med 10:33-9. 2004
    ..These findings provide insight toward the design of new antiandrogens...
  43. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  44. ncbi Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Cell 8:393-406. 2005
    ....
  45. ncbi LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
    Eric Metzger
    Universitäts Frauenklinik und Zentrum für Klinische Forschung, Klinikum der Universität Freiburg, Breisacherstrasse 66, 79106 Freiburg, Germany
    Nature 437:436-9. 2005
    ..Here, we link demethylation of a repressive histone mark with androgen-receptor-dependent gene activation, thus providing a mechanism by which demethylases control specific gene expression...
  46. pmc Mouse DNA contamination in human tissue tested for XMRV
    Mark J Robinson
    Section of Infectious Diseases, Jefferiss Research Trust Laboratories, Imperial College London, St Mary s Campus, London, W2 1PG, UK
    Retrovirology 7:108. 2010
    ..To control for contamination, PCR assays to detect either mouse mitochondrial DNA (mtDNA) or intracisternal A particle (IAP) long terminal repeat DNA were run on all samples, owing to their very high copy number in mouse cells...
  47. ncbi Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy
    Yan Ping Yu
    University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    J Clin Oncol 22:2790-9. 2004
    ..Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology...
  48. ncbi Androgen receptor in prostate cancer
    Cynthia A Heinlein
    George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, Rochester, NY 14642, USA
    Endocr Rev 25:276-308. 2004
    ..The inhibition of AR activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression...
  49. ncbi Permutation tests for joinpoint regression with applications to cancer rates
    H J Kim
    Syracuse University, Department of Mathematics, 215 Carnegie Building, Syracuse University, Syracuse, NY 13244 1150, USA
    Stat Med 19:335-51. 2000
    ..The performance of these tests are studied via simulations and the tests are applied to U.S. prostate cancer incidence and mortality rates...
  50. ncbi Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial
    Sean M McBride
    Harvard Radiation Oncology Program, Harvard University, 100 Blossom Street, 3, Boston, MA 02114, USA
    Cancer 118:3681-90. 2012
    ..Here, the authors report on their own multi-institutional experience with extreme hypofractionated stereotactic radiotherapy for early stage disease...
  51. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  52. ncbi miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1
    Silvia Galardi
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
    J Biol Chem 282:23716-24. 2007
    ....
  53. pmc Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
    Brett S Carver
    Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York, USA
    Nat Genet 41:619-24. 2009
    ..Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma...
  54. ncbi Circulating miRNAs are correlated with tumor progression in prostate cancer
    Jan C Brase
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg, Germany
    Int J Cancer 128:608-16. 2011
    ..Overall, our observations suggest that miRNA-375 and miRNA-141 expression is enhanced in prostate cancer specimens and their release into the blood is further associated with advanced cancer disease...
  55. ncbi Clinical features of metastatic bone disease and risk of skeletal morbidity
    Robert E Coleman
    Academic Unit of Medical Oncology, Weston Park Hospital, Sheffield, United Kingdom
    Clin Cancer Res 12:6243s-6249s. 2006
    ..Our improved understanding of prognostic and predictive factors may enable delivery of a more personalized treatment for the individual patient and a more cost-effective use of health care resources...
  56. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  57. pmc Transcriptome sequencing to detect gene fusions in cancer
    Christopher A Maher
    Michigan Center for Translational Pathology, Ann Arbor, USA
    Nature 458:97-101. 2009
    ..Taken together, this study establishes a robust pipeline for the discovery of novel gene chimaeras using high-throughput sequencing, opening up an important class of cancer-related mutations for comprehensive characterization...
  58. pmc XMRV: a new virus in prostate cancer?
    Amanda L Aloia
    HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA
    Cancer Res 70:10028-33. 2010
    ..It is possible that XMRV is not actually circulating in the human population; even if it is, the data do not seem to support a causal role for this virus in PCa...
  59. pmc Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation
    Laura Poliseno
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA 02215, USA
    Sci Signal 3:ra29. 2010
    ..Thus, we have uncovered a proto-oncogenic miRNA-dependent network for PTEN regulation and defined the MCM7 locus as a critical factor in initiating prostate tumorigenesis...
  60. pmc The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration
    Jichao Qin
    Department of Molecular Carcinogenesis, University of Texas M D Anderson Cancer Center, Science Park, Smithville, TX 78957, USA
    Cell Stem Cell 10:556-69. 2012
    ..Altogether, our study suggests that PSA(-/lo) cells may represent a critical source of castration-resistant PCa cells...
  61. pmc Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
    Biswajyoti Sahu
    Institute of Biomedicine, Physiology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    EMBO J 30:3962-76. 2011
    ..The role of FoxA1 in androgen signalling and prostate cancer is distinctly different from that in oestrogen signalling and breast cancer...
  62. pmc MicroRNAs associated with metastatic prostate cancer
    Akira Watahiki
    Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    PLoS ONE 6:e24950. 2011
    ..The objective of this study was to identify down- and up-regulated miRNAs in prostate cancer that could provide potential biomarkers and/or therapeutic targets for prostate cancer metastasis...
  63. pmc Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    JAMA 301:39-51. 2009
    ..Secondary analyses of 2 randomized controlled trials and supportive epidemiologic and preclinical data indicated the potential of selenium and vitamin E for preventing prostate cancer...
  64. ncbi Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression
    Honor Hugo
    Embryology Laboratory, Murdoch Children s Research Institute, The Royal Children s Hospital, Victoria, Australia
    J Cell Physiol 213:374-83. 2007
    ..Finally, perspectives from a clinical and translational viewpoint are discussed...
  65. pmc Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Karim Fizazi
    Institut Gustave Roussy, University of Paris Sud, Villejuif, France
    Lancet 377:813-22. 2011
    ..We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer...
  66. pmc Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
    Philip W Kantoff
    Medical Director, BN ImmunoTherapeutics, 2425 Garcia Ave, Mountain View, CA 94043, USA
    J Clin Oncol 28:1099-105. 2010
    ..PROSTVAC-VF treatment was evaluated for safety and for prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized, controlled, and blinded phase II study...
  67. pmc Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells
    Emily C Knouf
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Virol 83:7353-6. 2009
    ....
  68. ncbi Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    Johann S de Bono
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 14:6302-9. 2008
    ..Secondary objectives included determining the prognostic utility of CTC measurement before initiating therapy, and the relationship of CTC to prostate-specific antigen (PSA) changes and OS at these and other time points...
  69. ncbi Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143 1708, and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:965-74. 2006
    ..For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature...
  70. pmc Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells
    Claudia Andreu-Vieyra
    Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
    Mol Cell Biol 31:4648-62. 2011
    ..This allows the recruitment of histone modifiers, chromatin remodelers, and ultimately gene activation. The "receptive" state described here could help explain AR signaling activation under very low ligand concentrations...
  71. ncbi Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone
    Russell S Taichman
    Department of Periodontics, Prevention, and Geriatrics, and the Center for Biorestoration of Oral Health, School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109 1078, USA
    Cancer Res 62:1832-7. 2002
    ..Collectively, these results suggest that prostate cancers and perhaps other neoplasms may use the SDF-1/CXCR4 pathway to spread to bone...
  72. pmc Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers
    Akash Kumar
    Department of Genome Sciences, University of Washington, Seattle, WA 98105, USA
    Proc Natl Acad Sci U S A 108:17087-92. 2011
    ..Our results also suggest that increasingly deep catalogs of human germline variation may challenge the necessity of sequencing matched tumor-normal pairs...
  73. pmc Nucleosome dynamics define transcriptional enhancers
    Housheng Hansen He
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts, USA
    Nat Genet 42:343-7. 2010
    ..Therefore, quantitative modeling of enhancer structure provides a powerful predictive method to infer the identity of transcription factors involved in cellular responses to specific stimuli...
  74. ncbi Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force
    Roger Chou
    Oregon Health and Science University, Portland, Oregon 97239, USA
    Ann Intern Med 155:762-71. 2011
    ..Screening can detect prostate cancer at earlier, asymptomatic stages, when treatments might be more effective...
  75. ncbi Mechanisms of bone metastasis
    G David Roodman
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, School of Medicine Hematology, The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    N Engl J Med 350:1655-64. 2004
  76. pmc Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
    Shannon L Stott
    Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 107:18392-7. 2010
    ..In a subset of patient samples, the low shear design of the HB-Chip revealed microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer...
  77. pmc Molecular genetics of prostate cancer: new prospects for old challenges
    Michael M Shen
    Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA
    Genes Dev 24:1967-2000. 2010
    ..Overall, we highlight the tremendous research progress made in recent years, and underscore the challenges that lie ahead...
  78. pmc The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
    Charles E Massie
    CRUK Cambridge Research Institute, Cambridge, UK
    EMBO J 30:2719-33. 2011
    ..In conclusion, it is possible to progress from transcriptional studies to a promising therapeutic target by taking an unbiased interdisciplinary approach...
  79. pmc Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Lancet 379:39-46. 2012
    ..We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer...
  80. pmc Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
    Zsofia Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 43:785-91. 2011
    ..7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified...
  81. pmc An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors
    Beihua Dong
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Proc Natl Acad Sci U S A 104:1655-60. 2007
    ..Our studies demonstrate that XMRV is a virus that has infected humans and is susceptible to inhibition by IFN and its downstream effector, RNase L...
  82. ncbi Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation
    Yutaka Kondo
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Genet 40:741-50. 2008
    ..These data establish EZH2-mediated H3K27triM as a mechanism of tumor-suppressor gene silencing in cancer that is potentially independent of promoter DNA methylation...
  83. pmc Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
    Philip A Watson
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 107:16759-65. 2010
    ....
  84. pmc Identification of a cell of origin for human prostate cancer
    Andrew S Goldstein
    Molecular Biology Institute, University of California, Los Angeles UCLA, Los Angeles, CA 90095, USA
    Science 329:568-71. 2010
    ..Our results demonstrate that histological characterization of cancers does not necessarily correlate with the cellular origins of the disease...
  85. ncbi A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer
    Karsten Gravdal
    The Gade Institute, Section for Pathology, University of Bergen, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 13:7003-11. 2007
    ..We here present novel data, with special focus on the independent relationship between an E-cadherin to N-cadherin switch (EN-switch) and patient prognosis...
  86. ncbi Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 448:595-9. 2007
    ..Furthermore, the identification of androgen-repressed and insensitive 5' fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer...
  87. ncbi Prostate cancer incidence and mortality trends in 37 European countries: an overview
    F Bray
    Cancer Information Section, International Agency for Research on Cancer, Lyon, France
    Eur J Cancer 46:3040-52. 2010
    ..The increase in mortality observed in the Baltic region and in several Central and Eastern European countries appear to reflect a real increase in risk and requires further monitoring...
  88. ncbi Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
  89. ncbi Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells
    L Patrawala
    Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, 78957, USA
    Oncogene 25:1696-708. 2006
    ..Altogether, our results suggest that the CD44(+) PCa cell population is enriched in tumorigenic and metastatic progenitor cells...
  90. ncbi Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
    Jennifer A Locke
    Department of Urologic Sciences, University of British Columbia, The Prostate Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada
    Cancer Res 68:6407-15. 2008
    ..This evidence suggests that de novo androgen synthesis may be a driving mechanism leading to CRPC progression following castration...
  91. ncbi Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer
    Zumre A Alicikus
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:1429-37. 2011
    ..The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer...
  92. pmc miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth
    Judit Ribas
    The James Buchanan Brady Urological Institute, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 69:7165-9. 2009
    ..Moreover, quantitative reverse transcription-PCR analysis revealed elevated miR-21 expression in CaP when compared with adjacent normal tissue. These results suggest that miR-21 may contribute to CaP pathogenesis...
  93. ncbi Effect of dutasteride on the risk of prostate cancer
    Gerald L Andriole
    Division of Urology, Washington University School of Medicine in St Louis, St Louis, MO 63110, USA
    N Engl J Med 362:1192-202. 2010
    ..We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease...
  94. pmc Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
    Shihua Sun
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98104, USA
    J Clin Invest 120:2715-30. 2010
    ....
  95. ncbi Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
    Raymond J Andersen
    Chemistry and Earth and Ocean Sciences, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1
    Cancer Cell 17:535-46. 2010
    ..Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity...
  96. ncbi Radiation-induced second cancers: the impact of 3D-CRT and IMRT
    Eric J Hall
    Center for Radiological Research, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Int J Radiat Oncol Biol Phys 56:83-8. 2003
    ..75% for patients surviving 10 years. The numbers may be larger for longer survival (or for younger patients), but the ratio should remain the same...
  97. ncbi Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
    Shunyou Wang
    Howard Hughes Medical Institute, University of California Los Angeles School of Medicine, 90095, Los Angeles, CA, USA
    Cancer Cell 4:209-21. 2003
    ..This murine prostate cancer model provides a unique tool for both exploring the molecular mechanism underlying prostate cancer and for development of new targeted therapies...
  98. pmc Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells
    Dejuan Kong
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States of America
    PLoS ONE 5:e12445. 2010
    ..Increasing evidence suggests that EMT-type cells share many biological characteristics with cancer stem-like cells...
  99. pmc Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer
    R E Reiter
    Department of Urology, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 95:1735-40. 1998
    ..A mouse homologue with 70% amino acid identity and similar genomic organization to human PSCA has also been identified. These results support PSCA as a target for prostate cancer diagnosis and therapy...
  100. pmc Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
    Rong Hu
    Department of Urology, Oncology, and Pathology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Cancer Res 69:16-22. 2009
    ..In addition, as expression markers for lethal PCa, these novel AR variants may be explored as potential biomarkers and therapeutic targets for advanced PCa...
  101. ncbi Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer
    E S Martens-Uzunova
    Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    Oncogene 31:978-91. 2012
    ..Our findings provide miRNA expression signatures that may serve as an accurate tool for the diagnosis and prognosis of PCa...

Research Grants63

  1. Dietary Folate: Impact on Prostate Tumor Biology, Genetics and Epigenetics
    DOMINIC JAMES SMIRAGLIA; Fiscal Year: 2010
    ..If so, this could have very important implications for prostate cancer in men allowing us to slow the progression in men showing the very first signs of prostate cancer and therefore significantly reducing mortality from this disease. ..
  2. Diet change among prostate cancer patients under expectant management
    James Marshall; Fiscal Year: 2013
    ..This proposal is to investigate whether a dietary intervention emphasizing a plant-based diet slows or blocks progression of prostate cancer. ..
  3. New Mice Models for Studies of Androgen Receptor in Prostate Cancer
    Shuyuan Yeh; Fiscal Year: 2012
    ..In addition, these mice models may be useful for testing new drugs and treatments for prostate cancer therapy, which might eventually be used in humans. ..
  4. PREVENTION AND TREATMENT OF IMPOTENCE
    Tom F Lue; Fiscal Year: 2013
    ....
  5. Temperature Modulated-Fluorescence Tomography: A New Modality for Cancer Imaging
    TIFFANY KWONG; Fiscal Year: 2013
    ..If successful, the outcome will be the beginning of a new imaging modality. ..
  6. External validation of GEMCaP, a prognostic DNA biomarker set for CaP recurrence
    Pamela L Paris; Fiscal Year: 2013
    ....
  7. Dietary Inorganic Phosphate as a Target for Nutritional intervention in Cancer
    George R Beck; Fiscal Year: 2010
    ....
  8. MESENCHYMAL DERIVED GROWTH FACTORS IN PROSTATIC CANCER
    David R Rowley; Fiscal Year: 2013
    ..Dissecting these processes and key pathways is important for long-range studies that will focus on directed therapeutics that target the reactive stroma compartment in human prostate cancer. ..
  9. Robot-assisted prostate surgery using augmented reality with deformable models
    Peter Kazanzides; Fiscal Year: 2011
    ..To address this need, we propose to develop an augmented reality display for improved visualization of the prostate and surrounding critical anatomy robot-assisted prostate surgery. ..
  10. INTER ALPHA TRYPSIN INHIBITOR IN CAOX UROLITHIASIS
    Susan Ruth Marengo; Fiscal Year: 2002
    ..e. the liver the primary source of serum IaTI- trimer), or locally (kidney) as judged by Northern blot analysis of RNA message for each of the IaTI-subunits and by Western blot/ELISA of the protein. ..
  11. AGING AND MALE REPRODUCTIVE TRACT STRUCTURE/FUNCTION
    Barry Zirkin; Fiscal Year: 2002
    ..Brown, Project 2), Sertoli/germ (Drs. Zirkin and Wright, Project 1), spermatozoal (Dr. Robaire, Project 3) and epididymal (Dr. Robaire, Project 3) cells, and to determine the mechanism by which such changes occur. ..
  12. Computer Directed Photodynamic Therapy of Prostate Ca
    Jerzy Jankun; Fiscal Year: 2005
    ....
  13. STUDIES OF HUMAN MALE INFERTILITY
    Philip Troen; Fiscal Year: 1980
    ..We also plan to extend our studies of intratesticular steroidogenesis and androgen binding protein to subhuman primates. Such experiments will permit us to explore the control of testicular hormones in a fashion not possible in man. ..
  14. ANDROGEN RECEPTORS IN CANCEROUS PROSTATIC TISSUE
    Donald Tindall; Fiscal Year: 1993
    ..This would be a new diagnostic tool for evaluating potential treatment protocols in arresting this disease...
  15. CHEMICAL INDUCTION OF PROSTATIC ADENOCARCINOMAS
    Maarten Bosland; Fiscal Year: 1993
    ..For this purpose, tumors will be transplanted into intact, castrated and androgen-treated rats. ..
  16. DIETARY SOY EFFECTS ON MARKERS OF PROSTATE CANCER
    W Lee; Fiscal Year: 2000
    ..Evidence for target organ activity with an excellent quality of life profile will provide valuable information for further investigations in the use of soy supplementation to prevent the development of prostate cancer. ..
  17. Cell Growth Inhibiton and Estrogen Action
    Barry Markaverich; Fiscal Year: 2004
    ..The proposed studies should precisely define specific effects of MeHPLA and bioflavonoids on chromatin structure and function, growth related gene transcription and cellular proliferation in normal and malignant cells. ..
  18. Novel Drug Development for Prostatic Cancer
    Saeed Khan; Fiscal Year: 2006
    ..These studies will serve to identify the best candidate prodrug that will be subsequently tested in clinical trials as treatment for metastatic prostate cancer. ..
  19. HIGH FAT DIET IN EXPERIMENTAL PROSTATIC CANCER
    PARVIZ POUR; Fiscal Year: 1990
    ..e. T, estradiol (E), follicle stimulating hormone (FSH) and prolactin)?..
  20. Chronobiological Principles to Maximize Efficacy of Alt*
    Jack Burton; Fiscal Year: 2004
    ..The results of this work will lend itself to (a) future chronobiological studies of other dietary agents for both therapy and chemoprevention and (b) translation of results into clinical trials. ..
  21. BIOMORPHOMETRY OF HUMAN PROSTATIC CANCER
    PRIYA WERAHERA; Fiscal Year: 2005
    ....
  22. Anti-PAM Inhibitors for the Treatment of Cancer
    DAVID MERKLER; Fiscal Year: 2002
    ..The successful completion of this research will validate PAM a about target for anticancer drugs and will lead to chemotherapeutics that could prove broadly useful in the treatment of cancer. ..
  23. ULTRASOUND DETECTION AND STAGING OF PROSTATIC CANCER
    Joseph Smith; Fiscal Year: 1992
    ..A statistical and coordinating center has been established to record and analyze the results. Serum will be stored in a central bank and prostate specific antigen performed all on patients at a core laboratory...
  24. PROSTATIC CANCER: GENETIC AND ENDOCRINE RISK FACTORS
    A Meikle; Fiscal Year: 1980
    ..The investigation is feasible because of the availability of a population with large families and a high incidence of prostatic cancer...
  25. IMMUNODIAGNOSIS OF PROSTATIC CANCER
    CHING LI LEE; Fiscal Year: 1980
    ..Patients with cancer of the prostate and other tumors as well as controls will be evaluated. The ultimate goal of this proposal is to detect, by means of immunodiagnosis, the early, localized and treatable prostatic tumor. ..
  26. NORMAL TISSUE DOSE VOLUME RESPONSE IN RADIATION THERAPY
    Timothy Schultheiss; Fiscal Year: 2002
    ..This form of data splitting will be used to determine if the model(s) fit the new data, thereby validating the initial results. ..
  27. Novel Molecular Profiling of Prostate Cancer Signatures
    Shao Yao Ying; Fiscal Year: 2006
    ..These results may pave the way for a precise gene-chip diagnosis of stage-specific markers of human prostate cancer. ..
  28. MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER
    George Michalopoulos; Fiscal Year: 2004
    ..abstract_text> ..
  29. ENVIRONMENT & GLI GENES IN NORMAL DEVELOPMENT & DISEASE
    Philip Iannaccone; Fiscal Year: 2004
    ..Clearly understanding the pathways and the biochemical mechanism of action of developmental genes will be necessary in order to determine the role of environmental exposures on human health. ..
  30. HORMONE AND RADIATION THERAPY OF PROSTATIC TUMORS
    Warren Heston; Fiscal Year: 1980
    ..The effect of single and fractionated doses of irradiation on the tumor will be determined by histologic examination, tumor size, clonogenic assay, metastasis, and tumor progression...
  31. ESTRAMUSTINE AS AN ANTIMICROTUBULE AGENT IN THE PROSTATE
    Kenneth Tew; Fiscal Year: 1993
    ..Of further significance, the drug is already proving to be a valuable tool for probing the role of MAPs in cytoskeletal structure. Continued progress will consolidate and expand the utility of the drug as an aid to cell biologists...
  32. TESTOSTERONE REGULATION OF THROMBOXANE A2 RECEPTORS
    Perry Halushka; Fiscal Year: 1999
    ..The goal of all these studies is to provide new information concerning the potential role of testosterone to regulate the expression of Thromboxane A2 receptors and modulate platelet and vascular reactivity in humans. ..
  33. Metallothionein & Cadmium Carcinogenesis in the Prostate
    Shuk Mei Ho; Fiscal Year: 2006
    ..abstract_text> ..
  34. USE OF THE MOUSE FOR PROSTATE CANCER GENE DISCOVERY
    DIEGO CASTRILLON; Fiscal Year: 2004
    ..He also holds a Ph.D. in genetics and developmental biology. The research will be carried out in a cancer biology laboratory within the Dana Farber Cancer Institute, an affiliate of the Harvard Medical School. ..
  35. MOLECULAR CLASSIFICATION OF PROSTATE CANCER
    William Gerald; Fiscal Year: 2004
    ..abstract_text> ..
  36. DEVELOPMENT OF MOLECULAR MARKERS FOR PROSTATE CANCER
    Carrie Rinker Schaeffer; Fiscal Year: 2000
    ..Once identified, the metastasis-suppressor genes will be tested for their ability to accurately substage clinical prostatic cancer samples. ..
  37. HUMAN ANDROGEN RECEPTOR--PURIFICATION AND CLONING
    OLLI JANNE; Fiscal Year: 1990
    ..Achievement of these goals would be a major step in furthering our understanding of androgen action as it relates to basic mechanisms and/or clinical medicine...
  38. ANDROGEN THERAPY--BIOLOGICAL AND CLINICAL CONSEQUENCES
    Richard Santen; Fiscal Year: 1990
    ..Compilation of the material presented at this meeting in a critical, timely way will provide direction to investigators working in this field with respect to potential areas of investigation...
  39. Prostate Cancer Education in African American Men
    STEPHEN LEPORE; Fiscal Year: 2007
    ....
  40. BREAST CANCER
    THOMAS PRETLOW; Fiscal Year: 1980
    ....
  41. INDUCTION AND ANALYSIS OF PROSTATE CANCER
    James Norris; Fiscal Year: 2001
    ....
  42. PROSTATE CANCER CHEMOPREVENTION BY COX 2 INHIBITION
    Hasan Mukhtar; Fiscal Year: 2002
    ..We believe that the outcome of this proposal will set a platform to define the use of selective COX-2 inhibitors against prevention of CaP in humans. ..
  43. ASSOCIATION OF PROSTATE METASTASES AND DRUG RESISTANCE
    Mark Stearns; Fiscal Year: 1992
    ..Continued progress will consolidate and expand the utility of the drug as an aid to understanding molecular mechanisms regulating metastases...
  44. FIBROBLAST REGULATION OF HUMAN PROSTATIC CARCINOGENESIS
    Thea Tlsty; Fiscal Year: 2003
    ..In this proposal, we have focused our attention on identifying fibroblast-induced signals which contribute to prostatic tumor progression. ..
  45. ROLE OF GROWTH FACTORS IN HUMAN PROSTATE CARCINOMA
    Joy Ware; Fiscal Year: 1992
    ..Equally significant, these experiments will permit experimental evaluation of the relation between expression of these genes and the pathobiological phenotype of this common human tumor...
  46. MICROWAVE TREATMENT OF LOCALIZED PROSTATE CANCER
    FRED STERZER; Fiscal Year: 2000
    ..The new type of catheters developed during the proposed program and the associated hyperthermia equipment will be important commercial products. ..
  47. REGULATORY MECHANISMS OF PROSTATE TUMOR PROGRESSION
    Warren Heston; Fiscal Year: 2002
    ..These projects and the recruitment of developmental programs to the Center are designed to provide an understanding of the biology of progression of CaP and developing strong rational for innovative interventional strategies. ..
  48. MID ATLANTIC PROSTATE CANCER BANK
    Jan Orenstein; Fiscal Year: 2004
    ..This resource will assure that investigators will obtain optimal research specimens with clinical-pathologic correlation for their studies. ..
  49. CONTROLLED INTRACAVITARY PROSTATE CANCER HYPERTHERMIA
    KENNETH CARR; Fiscal Year: 1993
    ..Combining the PMR system with newly designed transrectal and transurethral applicators should allow intracavitary prostate hyperthermia treatments to be delivered without the need for additional invasive thermometry...
  50. IMMUNOCHEMICAL STUDIES OF PROSTATIC ACID PHOSPHATASE
    Byung Kil Choe; Fiscal Year: 1980
    ....
  51. PROGRAMMED DEATH OF NORMAL & MALIGNANT PROSTATIC CELLS
    John Isaacs; Fiscal Year: 1992
    ..Therefore, the PI proposes to initiate a series of very basic but fundamental questions concerning the programmed cell death process in normal and malignant prostatic cells...
  52. HUMAN PROSTATIC CANCER CELL CULTURES FOR DRUG EVALUATION
    P Iype; Fiscal Year: 1992
    ..Because of the health relatedness of this project, it is highly relevant to the mission and objectives of the National Institutes of Health...
  53. SYSTEMATIC ASSESS OF GENE EXPRESSION IN MOUSE PROSTATE
    Yong Chen; Fiscal Year: 2002
    ..The data should be a rich, valuable resource for devising future genetic targeting, animal modeling and other experiments related to developmental biology in general and prostate cancer in particular. ..
  54. Improved Reagents for Prostate Cancer Imaging
    Alton Boynton; Fiscal Year: 2004
    ..An imaging reagent utilizing antibodies capable of strong and efficient binding to live prostate cancer cells would be expected to provide dramatically improved capability compared to current methods ..
  55. ANTIBODY TARGETING TO PSMA IN PROSTATIC TUMORS
    Eric Holmes; Fiscal Year: 1999
    ..Application of antibody targeting of therapeutic agents to prostate cancer via markers such as prostate-specific membrane antigen should be specific and result in new means to treat advanced disease. ..
  56. Adipose-Related Biomarkers of Prostate Cancer
    JAY FOWKE; Fiscal Year: 2004
    ..Greater body adiposity may advance prostate carcinogenesis through an estrogen mechanism, and an analysis of adipose-related biomarkers may suggest that weight reduction would decrease CaP risk or improve prognosis. ..
  57. PROSTATIC VASCULOGENIC MIMICRY: A NEW METASTATIC PATHWAY
    Mary Hendrix; Fiscal Year: 2003
    ..cell lines strongly support the concept that "vasculogenic mimicry" is also exhibited by aggressive prostatic neoplasms. The overall objective of this proposed research, therefore, is to determine the key molecular mechanisms ..
  58. IMAGING TECHNIQUES IN PROSTATE CANCER
    David Paushter; Fiscal Year: 1991
    ..4. To evaluate the role of these new modalities as possible screening of populations at risk of developing prostate carcinoma...
  59. ANDROGEN RECEPTOR COREPRESSORS IN PROSTATE CANCER
    Derek Solum; Fiscal Year: 2005
    ....
  60. Primary Prevention Versus Screening for Prostate Cancer
    Ruth Etzioni; Fiscal Year: 2005
    ..The final model will be made available to investigators through a dedicated website which will allow users to run the model with their own settings for key cost and efficacy parameters. ..
  61. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  62. Immunoglobulin Allotypes in Hepatitis C Virus Infection
    JANARDAN PANDEY; Fiscal Year: 2008
    ..Results of this investigation will advance our understanding of the role of host genetic factors in clearance and persistence of hepatitis C virus infection. ..